The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The glucometer connects to one’s smartphone and provides actionable diagnostic information
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Subscribe To Our Newsletter & Stay Updated
